Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sEphB4-HSA and Keytruda in NSCLC and head and neck cancer
NCT03049618Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Mar 2017
- Primary completion
- Sep 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of sephb4-hsa in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), sponsored by University of Southern California. Started Mar 2017; status: completed.
02
Drugs
sephb4-hsa
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03049618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03049618.